Tokio Marine Asset Management Co. Ltd. Purchases 748 Shares of Hologic, Inc. (NASDAQ:HOLX)

Tokio Marine Asset Management Co. Ltd. raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,007 shares of the medical equipment provider’s stock after purchasing an additional 748 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Hologic were worth $489,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Innealta Capital LLC bought a new stake in Hologic during the second quarter valued at approximately $25,000. Wolff Wiese Magana LLC purchased a new position in shares of Hologic during the 3rd quarter worth $25,000. iA Global Asset Management Inc. bought a new stake in shares of Hologic during the 1st quarter valued at $37,000. Sunbelt Securities Inc. purchased a new stake in shares of Hologic in the 2nd quarter worth $37,000. Finally, Cromwell Holdings LLC raised its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.4 %

Shares of HOLX stock opened at $78.60 on Friday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $18.26 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 2.50 and a beta of 0.98. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The stock’s 50-day moving average price is $80.71 and its 200-day moving average price is $78.25.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS. Equities research analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on HOLX. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and cut their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.